- Home
- JCE vs VNDA Comparison
JCE vs VNDA Comparison
Compare JCE & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JCE
- VNDA
- Stock Information
- Founded
- JCE 2007
- VNDA 2002
- Country
- JCE United States
- VNDA United States
- Employees
- JCE N/A
- VNDA N/A
- Industry
- JCE Trusts Except Educational Religious and Charitable
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- JCE Finance
- VNDA Health Care
- Exchange
- JCE Nasdaq
- VNDA Nasdaq
- Market Cap
- JCE 262.6M
- VNDA 249.4M
- IPO Year
- JCE N/A
- VNDA 2006
- Fundamental
- Price
- JCE $15.71
- VNDA $4.61
- Analyst Decision
- JCE
- VNDA Strong Buy
- Analyst Count
- JCE 0
- VNDA 2
- Target Price
- JCE N/A
- VNDA $16.50
- AVG Volume (30 Days)
- JCE 49.7K
- VNDA 460.3K
- Earning Date
- JCE 01-01-0001
- VNDA 11-05-2025
- Dividend Yield
- JCE 9.26%
- VNDA N/A
- EPS Growth
- JCE N/A
- VNDA N/A
- EPS
- JCE N/A
- VNDA N/A
- Revenue
- JCE N/A
- VNDA $203,467,000.00
- Revenue This Year
- JCE N/A
- VNDA $15.45
- Revenue Next Year
- JCE N/A
- VNDA $37.82
- P/E Ratio
- JCE N/A
- VNDA N/A
- Revenue Growth
- JCE N/A
- VNDA 11.78
- 52 Week Low
- JCE $11.64
- VNDA $3.81
- 52 Week High
- JCE $14.28
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- JCE 56.15
- VNDA 51.38
- Support Level
- JCE $15.55
- VNDA $4.54
- Resistance Level
- JCE $15.87
- VNDA $4.92
- Average True Range (ATR)
- JCE 0.16
- VNDA 0.19
- MACD
- JCE 0.01
- VNDA 0.02
- Stochastic Oscillator
- JCE 54.84
- VNDA 38.00
About JCE Nuveen Core Equity Alpha Fund of Beneficial Interest
Nuveen Core Equity Alpha Fund is a diversified closed-end management investment company. Its investment objective is to provide an attractive level of total return, through long-term capital appreciation and through income and gains. The Fund invests in a portfolio of actively managed large-capitalization U.S. common stocks, using the sub-adviser's proprietary quantitative process designed to provide the potential for long-term outperformance. Additionally, the Fund seeks to reduce the volatility of its returns relative to the returns of the Equity Portfolio over extended periods by writing (selling) index call options and/or call options on custom baskets of securities.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.